Montelukast Pour Les Enfants Âgés De 6 Mois À 5 Ans Teva

Montelukast, the active ingredient in Montelukast Pour Les Enfants Âgés De 6 Mois À 5 Ans Teva, is a leukotriene receptor antagonist presented as an oral dosage form for buccal use. It is used to manage asthma, exercise‑induced bronchoconstriction and allergic rhinitis in children aged six months to five years.

GNH USA supplies Montelukast Pour Les Enfants Âgés De 6 Mois À 5 Ans Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms. - Asthma: reduces the frequency of asthma attacks and improves overall disease control in young children. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways that occurs during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Sore throat - Nausea - Diarrhea

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema, or anaphylaxis - Neuropsychiatric events including depression or suicidal thoughts - Hepatic enzyme elevation - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe bronchospasm despite therapy

Montelukast should be used with attention to specific safety considerations. - Age limitation: indicated for children 6 months to 5 years only. - Medical history: assess liver function before initiating therapy. - Concomitant medications: review potential drug interactions. - Monitoring: observe for neuropsychiatric symptoms during treatment. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Montelukast may interact with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Phenobarbital: may lower montelukast plasma concentrations. - Rifampin: can reduce therapeutic effectiveness. - Ketoconazole: may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect. - Beta‑agonists: additive bronchodilation may occur, requiring dose adjustment.